{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:23:07Z","timestamp":1791501787703,"version":"4.3.4"},"reference-count":108,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T00:00:00Z","timestamp":1542672000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"DOI":"10.3389\/fphys.2018.01663","type":"journal-article","created":{"date-parts":[[2018,11,20]],"date-time":"2018-11-20T06:57:39Z","timestamp":1542697059000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":107,"title":["New Approaches to Tay-Sachs Disease Therapy"],"prefix":"10.3389","volume":"9","author":[{"given":"Valeriya V.","family":"Solovyeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alisa A.","family":"Shaimardanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria S.","family":"Chulpanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina V.","family":"Kitaeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Chakrabarti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert A.","family":"Rizvanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,11,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4805","DOI":"10.1128\/AEM.00463-07","article-title":"Production of recombinant beta-hexosaminidase A, a potential enzyme for replacement therapy for Tay-Sachs and Sandhoff diseases, in the methylotrophic yeast Ogataea minuta.","volume":"73","author":"Akeboshi","year":"2007","journal-title":"Appl. Environ. Microbiol."},{"key":"B2","first-page":"769","article-title":"Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adenoviral vector-mediated gene transfer.","volume":"3","author":"Akli","year":"1996","journal-title":"Gene Ther."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency\u2013macrophage-targeted glucocerebrosidase for Gaucher\u2019s disease.","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/dmcn.13600","article-title":"Treatment strategies for lysosomal storage disorders.","volume":"60","author":"Beck","year":"2018","journal-title":"Dev. Med. Child Neurol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.2174\/138161208784705504","article-title":"Lysosomal storage diseases and the blood-brain barrier.","volume":"14","author":"Begley","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"B6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1212\/01.wnl.0000194225.78917.de","article-title":"Substrate reduction therapy in the infantile form of Tay-Sachs disease.","volume":"66","author":"Bembi","year":"2006","journal-title":"Neurology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.ymgme.2014.05.009","article-title":"Pharmacological chaperones increase residual beta-galactocerebrosidase activity in fibroblasts from Krabbe patients.","volume":"112","author":"Berardi","year":"2014","journal-title":"Mol. Genet. Metab."},{"key":"B8","doi-asserted-by":"publisher","first-page":"R65","DOI":"10.1093\/hmg\/ddv457","article-title":"Gene therapy for lysosomal storage disorders: a good start.","volume":"25","author":"Biffi","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"B9","doi-asserted-by":"publisher","first-page":"e1233","DOI":"10.1542\/peds.2011-0078","article-title":"Natural history of infantile G(M2) gangliosidosis.","volume":"128","author":"Bley","year":"2011","journal-title":"Pediatrics"},{"key":"B10","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s10719-010-9278-1","article-title":"Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells.","volume":"27","author":"Boomkamp","year":"2010","journal-title":"Glycoconj. J."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1038\/mt.2013.86","article-title":"Therapeutic response in feline sandhoff disease despite immunity to intracranial gene therapy.","volume":"21","author":"Bradbury","year":"2013","journal-title":"Mol. Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"10373","DOI":"10.1073\/pnas.0603765103","article-title":"Effective gene therapy in an authentic model of Tay-Sachs-related diseases.","volume":"103","author":"Cachon-Gonzalez","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1038\/mt.2012.44","article-title":"Gene transfer corrects acute GM2 gangliosidosis\u2013potential therapeutic contribution of perivascular enzyme flow.","volume":"20","author":"Cachon-Gonzalez","year":"2012","journal-title":"Mol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1093\/hmg\/ddt459","article-title":"Reversibility of neuropathology in Tay-Sachs-related diseases.","volume":"23","author":"Cachon-Gonzalez","year":"2014","journal-title":"Hum. Mol. Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1007\/BF00292433","article-title":"Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease.","volume":"6","author":"Cohen-Tannoudji","year":"1995","journal-title":"Mamm. Genome"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3310\/hta10240","article-title":"The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher\u2019s disease: a systematic review.","volume":"10","author":"Connock","year":"2006","journal-title":"Health Technol. Assess"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17071065","article-title":"Less is more: substrate reduction therapy for lysosomal storage disorders.","volume":"17","author":"Coutinho","year":"2016","journal-title":"Int. J. Mol. Sci."},{"key":"B18","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/mus.24146","article-title":"Atypical presentation of late-onset Tay-Sachs disease.","volume":"49","author":"Deik","year":"2014","journal-title":"Muscle Nerve"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s11011-017-0044-y","article-title":"The treatment of juvenile\/adult GM1-gangliosidosis with Miglustat may reverse disease progression.","volume":"32","author":"Deodato","year":"2017","journal-title":"Metab. Brain Dis."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1091\/mbc.E16-01-0012","article-title":"Tay-Sachs disease mutations in HEXA target the alpha chain of hexosaminidase A to endoplasmic reticulum-associated degradation.","volume":"27","author":"Dersh","year":"2016","journal-title":"Mol. Biol. Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease.","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3233\/TRD-160005","article-title":"Lysosomal storage diseases.","volume":"2","author":"Ferreira","year":"2017","journal-title":"Transl. Sci. Rare Dis."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00628","article-title":"Human umbilical cord blood cell transplantation in neuroregenerative strategies.","volume":"8","author":"Galieva","year":"2017","journal-title":"Front. Pharmacol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2737","DOI":"10.1021\/jm201633y","article-title":"Rapid assembly of a library of lipophilic iminosugars via the thiol-ene reaction yields promising pharmacological chaperones for the treatment of Gaucher disease.","volume":"55","author":"Goddard-Borger","year":"2012","journal-title":"J. Med. Chem."},{"key":"B25","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1089\/hum.2016.109","article-title":"Direct intracranial injection of AAVrh8 encoding monkey beta-N-Acetylhexosaminidase causes neurotoxicity in the primate brain.","volume":"28","author":"Golebiowski","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"B26","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2174\/1871527315666160815164247","article-title":"Neural stem Cell transplantation and CNS diseases.","volume":"15","author":"Gonzalez","year":"2016","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"B27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.4155\/tde.10.50","article-title":"Viral vectors and delivery strategies for CNS gene therapy.","volume":"1","author":"Gray","year":"2010","journal-title":"Ther. Deliv."},{"key":"B28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/hum.2017.163","article-title":"Adeno-associated virus gene therapy in a sheep model of Tay-Sachs disease.","volume":"29","author":"Gray-Edwards","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"B29","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/hmg\/7.5.831","article-title":"Retrovirus-mediated enzymatic correction of Tay-Sachs defect in transduced and non-transduced cells.","volume":"7","author":"Guidotti","year":"1998","journal-title":"Hum. Mol. Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1093\/hmg\/8.5.831","article-title":"Adenoviral gene therapy of the Tay-Sachs disease in hexosaminidase A-deficient knock-out mice.","volume":"8","author":"Guidotti","year":"1999","journal-title":"Hum. Mol. Genet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.ymgme.2017.12.143","article-title":"Update on phase 1\/2 clinical trials for MPS I and MPS II using ZFN-mediated in vivo genome editing.","volume":"123","author":"Harmatz","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"B32","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.jpeds.2004.03.018","article-title":"Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).","volume":"144","author":"Harmatz","year":"2004","journal-title":"J. Pediatr."},{"key":"B33","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jocn.2017.10.011","article-title":"Alteration of cortical excitability and its modulation by Miglustat in Niemann-Pick disease type C.","volume":"47","author":"Hassan","year":"2018","journal-title":"J. Clin. Neurosci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.braindev.2009.01.007","article-title":"Unilaterally and rapidly progressing white matter lesion and elevated cytokines in a patient with Tay-Sachs disease.","volume":"32","author":"Hayase","year":"2010","journal-title":"Brain Dev."},{"key":"B35","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.1021\/bi9524575","article-title":"Direct determination of the substrate specificity of the alpha-active site in heterodimeric beta-hexosaminidase A.","volume":"35","author":"Hou","year":"1996","journal-title":"Biochemistry"},{"key":"B36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/0014-5793(89)80649-0","article-title":"The amino-terminal sequences in the pro-alpha and -beta polypeptides of human lysosomal beta-hexosaminidase A and B are retained in the mature isozymes.","volume":"249","author":"Hubbes","year":"1989","journal-title":"FEBS Lett."},{"key":"B37","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/sj.bmt.1705155","article-title":"Allogeneic BMT followed by substrate reduction therapy in a child with subacute Tay-Sachs disease.","volume":"36","author":"Jacobs","year":"2005","journal-title":"Bone Marrow Transplant."},{"key":"B38","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/BF03195237","article-title":"Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases.","volume":"48","author":"Jakobkiewicz-Banecka","year":"2007","journal-title":"J. Appl. Genet."},{"key":"B39","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.ymgme.2017.04.011","article-title":"Infantile gangliosidoses: mapping a timeline of clinical changes.","volume":"121","author":"Jarnes Utz","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"B40","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1093\/brain\/awg089","article-title":"Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis.","author":"Jeyakumar","year":"2003","journal-title":"Brain"},{"key":"B41","article-title":"\u201cHexosaminidase a deficiency,\u201d in","author":"Kaback","year":"1993","journal-title":"GeneReviews((R))"},{"key":"B42","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1089\/hum.2016.013","article-title":"Novel vector design and hexosaminidase variant enabling self-complementary adeno-associated virus for the treatment of Tay-Sachs disease.","volume":"27","author":"Karumuthil-Melethil","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B43","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1016\/j.bmc.2010.04.048","article-title":"2,5-Dideoxy-2,5-imino-d-altritol as a new class of pharmacological chaperone for Fabry disease.","volume":"18","author":"Kato","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1055\/s-2005-837543","article-title":"Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study.","volume":"36","author":"Klinge","year":"2005","journal-title":"Neuropediatrics"},{"key":"B45","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.molbrainres.2004.10.026","article-title":"beta-hexosaminidase lentiviral vectors: transfer into the CNS via systemic administration.","volume":"133","author":"Kyrkanides","year":"2005","journal-title":"Brain Res. Mol. Brain Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nm0496-424","article-title":"Expression of human beta-hexosaminidase alpha-subunit gene (the gene defect of Tay-Sachs disease) in mouse brains upon engraftment of transduced progenitor cells.","volume":"2","author":"Lacorazza","year":"1996","journal-title":"Nat. Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1590\/S0004-282X2006000100001","article-title":"Bone marrow transplantation in patients with storage diseases: a developing country experience.","volume":"64","author":"Lange","year":"2006","journal-title":"Arq. Neuropsiquiatr."},{"key":"B48","doi-asserted-by":"publisher","first-page":"111","DOI":"10.2147\/TACG.S85354","article-title":"Animal models of GM2 gangliosidosis: utility and limitations.","volume":"9","author":"Lawson","year":"2016","journal-title":"Appl. Clin. Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.jmb.2006.04.004","article-title":"Crystallographic structure of human beta-hexosaminidase A: interpretation of Tay-Sachs mutations and loss of GM2 ganglioside hydrolysis.","volume":"359","author":"Lemieux","year":"2006","journal-title":"J. Mol. Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2147\/TACG.S49628","article-title":"Tay-Sachs disease: current perspectives from Australia.","volume":"8","author":"Lew","year":"2015","journal-title":"Appl. Clin. Genet."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.3928\/19382359-20180424-01","article-title":"Enzyme replacement therapy: a review and its role in treating lysosomal storage diseases.","volume":"47","author":"Li","year":"2018","journal-title":"Pediatr. Ann."},{"key":"B52","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.scr.2016.08.010","article-title":"Generation of HEXA-deficient hiPSCs from fibroblasts of a Tay-Sachs disease patient.","volume":"17","author":"Liu","year":"2016","journal-title":"Stem Cell Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.ymgme.2009.06.005","article-title":"Substrate reduction therapy in juvenile GM2 gangliosidosis.","volume":"98","author":"Maegawa","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"B54","doi-asserted-by":"publisher","first-page":"e1550","DOI":"10.1542\/peds.2006-0588","article-title":"The natural history of juvenile or subacute GM2 gangliosidosis: 21 new cases and literature review of 134 previously reported.","volume":"118","author":"Maegawa","year":"2006","journal-title":"Pediatrics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0925-4439(99)00074-5","article-title":"Biochemical consequences of mutations causing the GM2 gangliosidoses.","volume":"1455","author":"Mahuran","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"B56","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/S0022-2836(03)00311-5","article-title":"The X-ray crystal structure of human beta-hexosaminidase B provides new insights into Sandhoff disease.","volume":"328","author":"Maier","year":"2003","journal-title":"J. Mol. Biol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S0022-2836(03)00216-X","article-title":"Crystal structure of human beta-hexosaminidase B: understanding the molecular basis of Sandhoff and Tay-Sachs disease.","volume":"327","author":"Mark","year":"2003","journal-title":"J. Mol. Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.bbmt.2005.09.016","article-title":"Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases.","volume":"12","author":"Martin","year":"2006","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B59","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1023\/A:1020256924099","article-title":"Restoration of the GM2 ganglioside metabolism in bone marrow-derived stromal cells from Tay-Sachs disease animal model.","volume":"27","author":"Martino","year":"","journal-title":"Neurochem. Res."},{"key":"B60","doi-asserted-by":"publisher","first-page":"20177","DOI":"10.1074\/jbc.M106164200","article-title":"Absence of metabolic cross-correction in Tay-Sachs cells: implications for gene therapy.","volume":"277","author":"Martino","year":"","journal-title":"J. Biol. Chem."},{"key":"B61","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/hmg\/ddi216","article-title":"A direct gene transfer strategy via brain internal capsule reverses the biochemical defect in Tay-Sachs disease.","volume":"14","author":"Martino","year":"2005","journal-title":"Hum. Mol. Genet."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1038\/mt.2011.27","article-title":"Therapeutic potential of intracerebroventricular replacement of modified human beta-hexosaminidase B for GM2 gangliosidosis.","volume":"19","author":"Matsuoka","year":"2011","journal-title":"Mol. Ther."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0039122","article-title":"Identification of novel mutations in HEXA gene in children affected with Tay Sachs disease from India.","volume":"7","author":"Mistri","year":"2012","journal-title":"PLoS One"},{"key":"B64","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/j.1651-2227.2002.tb03118.x","article-title":"Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report.","volume":"91","author":"Muenzer","year":"2002","journal-title":"Acta Paediatr. Suppl."},{"key":"B65","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1002\/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.0.CO;2-7","article-title":"Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene.","volume":"9","author":"Myerowitz","year":"1997","journal-title":"Hum. Mutat."},{"key":"B66","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1093\/hmg\/11.11.1343","article-title":"Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling.","volume":"11","author":"Myerowitz","year":"2002","journal-title":"Hum. Mol. Genet."},{"key":"B67","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1128\/JVI.77.4.2512-2521.2003","article-title":"Reduction of natural adenovirus tropism to the liver by both ablation of fiber-coxsackievirus and adenovirus receptor interaction and use of replaceable short fiber.","volume":"77","author":"Nakamura","year":"2003","journal-title":"J. Virol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.ymgme.2017.12.432","article-title":"Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: volumetric quantitative MRI study.","volume":"123","author":"Nestrasil","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"B69","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1172\/JCI2127","article-title":"Bone marrow transplantation prolongs life span and ameliorates neurologic manifestations in Sandhoff disease mice.","volume":"101","author":"Norflus","year":"1998","journal-title":"J. Clin. Invest."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-015-0260-7","article-title":"Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study.","volume":"10","author":"Osher","year":"2015","journal-title":"Orphanet J. Rare Dis."},{"key":"B71","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1089\/hum.2016.015","article-title":"Systemic gene transfer of a Hexosaminidase variant using an scaav9.47 vector corrects GM2 gangliosidosis in sandhoff mice.","volume":"27","author":"Osmon","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B72","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1002\/emmm.200900036","article-title":"Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics.","volume":"1","author":"Parenti","year":"2009","journal-title":"EMBO Mol. Med."},{"key":"B73","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3892\/ijmm.2012.1187","article-title":"New strategies for the treatment of lysosomal storage diseases (review).","volume":"31","author":"Parenti","year":"2013","journal-title":"Int. J. Mol. Med."},{"key":"B74","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/B978-0-444-59565-2.00039-3","article-title":"Gangliosidoses.","volume":"113","author":"Patterson","year":"2013","journal-title":"Handb. Clin. Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1039\/c7sc04712f","article-title":"Tuning protein folding in lysosomal storage diseases: the chemistry behind pharmacological chaperones.","volume":"9","author":"Pereira","year":"2018","journal-title":"Chem. Sci."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/hmg\/5.1.1","article-title":"Dramatically different phenotypes in mouse models of human Tay-Sachs and Sandhoff diseases.","volume":"5","author":"Phaneuf","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0844-0","article-title":"Miglustat in Niemann-Pick disease type C patients: a review.","volume":"13","author":"Pineda","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"B78","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1098\/rstb.2003.1279","article-title":"Substrate reduction therapy in mouse models of the glycosphingolipidoses.","volume":"358","author":"Platt","year":"2003","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"B79","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1126\/science.276.5311.428","article-title":"Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin.","volume":"276","author":"Platt","year":"1997","journal-title":"Science"},{"key":"B80","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1177\/0300985810388522","article-title":"Pathology of GM2 gangliosidosis in Jacob sheep.","volume":"48","author":"Porter","year":"2011","journal-title":"Vet. Pathol."},{"key":"B81","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/mt.2009.53","article-title":"The pharmacological chaperone N-butyldeoxynojirimycin enhances enzyme replacement therapy in Pompe disease fibroblasts.","volume":"17","author":"Porto","year":"2009","journal-title":"Mol. Ther."},{"key":"B82","first-page":"663","article-title":"The GM1 and GM2 gangliosidoses: natural history and progress toward therapy.","author":"Regier","year":"2016","journal-title":"Pediatr. Endocrinol. Rev."},{"key":"B83","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/8904_2015_469","article-title":"GM2-gangliosidosis, AB variant: clinical, ophthalmological, MRI, and molecular findings.","volume":"25","author":"Renaud","year":"2016","journal-title":"JIMD Rep."},{"key":"B84","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1038\/bmt.2008.62","article-title":"The controversial and changing role of haematopoietic cell transplantation for lysosomal storage disorders: an update.","author":"Rovelli","year":"2008","journal-title":"Bone Marrow Transplant."},{"key":"B85","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2174\/187152706777950738","article-title":"Molecular pathologies of and enzyme replacement therapies for lysosomal diseases.","volume":"5","author":"Sakuraba","year":"2006","journal-title":"CNS Neurol Disord. Drug Targets"},{"key":"B86","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.biochi.2016.05.004","article-title":"Neuronal sphingolipidoses: membrane lipids and sphingolipid activator proteins regulate lysosomal sphingolipid catabolism.","volume":"130","author":"Sandhoff","year":"2016","journal-title":"Biochimie"},{"key":"B87","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/BF00390234","article-title":"Biochemistry and genetics of gangliosidoses.","volume":"50","author":"Sandhoff","year":"1979","journal-title":"Hum. Genet."},{"key":"B88","doi-asserted-by":"publisher","first-page":"10195","DOI":"10.1523\/JNEUROSCI.0822-13.2013","article-title":"Gangliosides and gangliosidoses: principles of molecular and metabolic pathogenesis.","volume":"33","author":"Sandhoff","year":"2013","journal-title":"J. Neurosci."},{"key":"B89","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ng1095-170","article-title":"Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism.","volume":"11","author":"Sango","year":"1995","journal-title":"Nat. Genet."},{"key":"B90","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.expneurol.2017.09.012","article-title":"Murine Sialidase Neu3 facilitates GM2 degradation and bypass in mouse model of Tay-Sachs disease.","author":"Seyrantepe","year":"2018","journal-title":"Exp. Neurol."},{"key":"B91","doi-asserted-by":"crossref","first-page":"7692","DOI":"10.1016\/S0021-9258(18)83290-2","article-title":"Analysis of the glycosylation and phosphorylation of the lysosomal enzyme, beta-hexosaminidase B, by site-directed mutagenesis.","volume":"264","author":"Sonderfeld-Fresko","year":"1989","journal-title":"J. Biol. Chem."},{"key":"B92","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1002\/emmm.201202083","article-title":"A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA.","volume":"5","author":"Sorrentino","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"B93","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/8904_2017_76","article-title":"Haematopoietic stem cell transplantation arrests the progression of neurodegenerative disease in late-onset tay-sachs disease.","volume":"41","author":"Stepien","year":"2017","journal-title":"JIMD Rep."},{"key":"B94","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/BF00309622","article-title":"Neuropathology of mice with targeted disruption of Hexa gene, a model of Tay-Sachs disease.","volume":"89","author":"Taniike","year":"1995","journal-title":"Acta Neuropathol."},{"key":"B95","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.ymgme.2010.08.006","article-title":"Tay-Sachs disease in Jacob sheep.","volume":"101","author":"Torres","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1038\/mtm.2015.57","article-title":"Construction of a hybrid beta-hexosaminidase subunit capable of forming stable homodimers that hydrolyze GM2 ganglioside in vivo.","volume":"3","author":"Tropak","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"B97","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ana.22262","article-title":"Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis.","volume":"69","author":"Tsuji","year":"2011","journal-title":"Ann. Neurol."},{"key":"B98","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.ymgme.2014.11.015","article-title":"Biomarkers of central nervous system inflammation in infantile and juvenile gangliosidoses.","volume":"114","author":"Utz","year":"2015","journal-title":"Mol. Genet. Metab."},{"key":"B99","doi-asserted-by":"publisher","first-page":"10954","DOI":"10.1073\/pnas.97.20.10954","article-title":"Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation.","volume":"97","author":"Wada","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41436-018-0129-y","article-title":"The New York pilot newborn screening program for lysosomal storage diseases: report of the First 65,000 Infants.","author":"Wasserstein","year":"2018","journal-title":"Genet. Med."},{"key":"B101","doi-asserted-by":"crossref","first-page":"10039","DOI":"10.1016\/S0021-9258(19)50196-X","article-title":"Analysis of the glycosylation and phosphorylation of the alpha-subunit of the lysosomal enzyme, beta-hexosaminidase A, by site-directed mutagenesis.","volume":"267","author":"Weitz","year":"1992","journal-title":"J. Biol. Chem."},{"key":"B102","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1006\/exnr.1999.7158","article-title":"Engineering herpes simplex virus vectors for CNS applications.","volume":"159","author":"Wolfe","year":"1999","journal-title":"Exp. Neurol."},{"key":"B103","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s10545-006-0239-6","article-title":"Limitations of enzyme replacement therapy: current and future.","volume":"29","author":"Wraith","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"key":"B104","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase).","volume":"144","author":"Wraith","year":"2004","journal-title":"J. Pediatr."},{"key":"B105","doi-asserted-by":"publisher","first-page":"8425","DOI":"10.1073\/pnas.0400625101","article-title":"Deletion of macrophage-inflammatory protein 1 alpha retards neurodegeneration in Sandhoff disease mice.","volume":"101","author":"Wu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B106","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1074\/jbc.273.1.66","article-title":"Specificity of mouse GM2 activator protein and beta-N-acetylhexosaminidases A and B. Similarities and differences with their human counterparts in the catabolism of GM2.","volume":"273","author":"Yuziuk","year":"1998","journal-title":"J. Biol. Chem."},{"key":"B107","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.ymgme.2008.06.010","article-title":"Spontaneous appearance of Tay-Sachs disease in an animal model.","volume":"95","author":"Zeng","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0776-8","article-title":"Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.","volume":"13","author":"Zimran","year":"2018","journal-title":"Orphanet J. Rare Dis."}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2018.01663\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,6]],"date-time":"2022-09-06T14:03:28Z","timestamp":1662473008000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2018.01663\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,20]]},"references-count":108,"alternative-id":["10.3389\/fphys.2018.01663"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2018.01663","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,20]]},"article-number":"1663"}}